Cat Allergy Shot for Humans: FDA-Standardized SCIT Explained
This page is about cat allergy shots FOR HUMANS — subcutaneous immunotherapy (SCIT) for people who are allergic to cat dander. It is not about treating allergies IN your cat. Veterinary products like Cytopoint (Zoetis lokivetmab) and Apoquel (Zoetis oclacitinib) are not relevant here — they are for dogs. Human cat SCIT uses FDA-standardized extract with ~72% RCT symptom reduction.
7 peer-reviewed sources
Cat allergy shots for humans are SCIT using FDA-standardized cat-hair or cat-pelt extract (10,000 BAU/mL, Greer license #308). Alvarez-Cuesta 1994 and Varney 1997 DBPC RCTs confirm ~72% symptom reduction. Course: ~26-week build-up plus 3–5 years maintenance.
The essentials
This page is about cat allergy shots FOR HUMANS — subcutaneous immunotherapy (SCIT) given to people who are allergic to cat dander. It is not about treating allergies IN your cat. Veterinary products like Cytopoint (Zoetis lokivetmab) and Apoquel (Zoetis oclacitinib) are not relevant here — Cytopoint and Apoquel are both for dogs anyway, but they appear in search results because of overlapping consumer queries. For cats with feline atopic dermatitis, see a veterinarian, not an allergist. This page covers immunotherapy for human patients with cat-dander sensitization.
For HUMANS allergic to cats, the allergy shot is SCIT using FDA-standardized cat-hair or cat-pelt extract. Cat-hair and cat-pelt, both at 10,000 BAU/mL under Greer license #308, are the ONLY FDA-standardized mammalian allergen extracts in the US. This standardization means a therapeutic maintenance dose in one clinic is biochemically equivalent to the same dose in another — a consistency not available for dog, horse, or any other mammalian extract.
Fel d 1 is the dominant cat allergen — a 35–38 kDa tetrameric secretoglobin produced in sebaceous, salivary, anal, and lacrimal glands. It sensitizes 90–96% of cat-allergic patients (Satyaraj E et al., Allergy 2019; Grönlund H et al., Int Arch Allergy Immunol 2010). The therapeutic maintenance dose per Cox L et al. JACI 2011 PP3 is 1,000–4,000 BAU per injection (approximately 11–17 µg Fel d 1 per 0.5 mL). Standard regimen: approximately 26 weekly build-up injections, then every 2–4 weeks for 3–5 years maintenance.
A mandatory 30-minute post-injection observation period has historically been required at every conventional in-clinic SCIT visit per AAAAI/ACAAI standard of care, and that observation requirement is the reason UnitedHealthcare ended coverage of unsupervised home-administered SCIT effective January 1, 2023. Those concerns were about doing shots at home without safeguards — the gap that the Curex at-home program is built to close for eligible maintenance patients.
For patients who cannot accept the ~39 Year-1 in-clinic visit burden, two at-home paths exist. Cat is the one pet allergen where sublingual immunotherapy drops have DBPC RCT support: Alvarez-Cuesta E et al. (Allergy 2007;62:810–817) showed 59% symptom reduction versus placebo with no systemic reactions. Separately, this same cat-allergen immunotherapy can now be self-administered at home — Curex ships an at-home allergy shot kit in which a Fel d 1 serum is sterile-compounded to USP <797>, one weekly shot is self-given, the first dose and every dose change are supervised live over Zoom by a board-certified allergist, and a prescribed epinephrine auto-injector is confirmed on hand. Curex also offers at-home IgE component testing for the HUMAN cat-allergen panel — Fel d 1 (cat-specific secretoglobin), Fel d 2 (serum albumin), Fel d 4 (lipocalin), Fel d 7 (lipocalin) — distinguishing primary cat sensitization from lipocalin cross-reactivity originating in horse or dog exposure.
Noteworthy molecular fact: Fel d 4 shares ~67% sequence identity with horse Equ c 1 and dog Can f 6. A patient testing positive to total cat extract may actually be primarily sensitized to horse or dog via lipocalin cross-reactivity — in which case the immunotherapy plan changes entirely. Component-resolved testing identifies which allergen should anchor the treatment.
How allergy shots retrain your immune system
Human cat SCIT works by inducing immune tolerance to Fel d 1 through repeated controlled exposure. Over 3–5 years, the IgE-mediated allergic response is redirected toward IgG4 blocking antibodies and T-regulatory cell suppression, producing durable benefit that outlasts the treatment course.
Confirm Human Cat IgE Sensitization
A board-certified allergist confirms IgE-mediated sensitization to cat dander (Fel d 1 specifically) via skin prick test or serum IgE. Component testing distinguishes Fel d 1 (cat-specific) from Fel d 4 (cross-reactive lipocalin).
Build-Up Phase (weekly, ~26 weeks)
Injections begin at a fraction of the therapeutic dose and increase stepwise over approximately 26 weekly in-clinic visits. A 30-minute post-injection observation period is mandatory at every visit per AAAAI standard of care.
Maintenance Phase (every 2–4 weeks, 3–5 years)
Once the therapeutic 1,000–4,000 BAU dose per Cox 2011 PP3 is reached, injections extend to every 2–4 weeks for 3–5 years. Consistent dosing is essential — gaps beyond 5 weeks require dose reductions.
Post-Treatment Remission (7–12+ years)
Durham SR et al. (NEJM 1999;341:468–475) documented at least 4-year sustained remission after a 3-year SCIT course. Estimated 7–12-year post-treatment benefit after a complete course.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
The cat SCIT timeline for humans follows the standard AAAAI/ACAAI three-phase structure. Total course: approximately 95–119 in-clinic visits over 3–5 years.
Weekly escalating in-office injections from the starting fraction of the therapeutic dose. A mandatory 30-minute observation period is required at every visit.
Year 1: approximately 39 total in-clinic visits. Years 2–5: approximately 14–20 visits/year. Minimum 3-year duration for durable disease modification.
After a complete 3-to-5-year course, immune tolerance persists. Post-treatment remission is the key disease-modifying outcome distinguishing immunotherapy from pharmacotherapy.
Efficacy by allergen — what the data shows
Human cat SCIT has the strongest evidence base of any pet-allergen immunotherapy. FDA standardization enables consistent therapeutic dosing — the central structural advantage over dog or horse SCIT.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Human cat-allergic patients choose between SCIT — available in-office or as an at-home allergy shot kit — and at-home SLIT drops. Cat is the one pet allergen where both modalities have DBPC RCT evidence. Veterinary products (Cytopoint, Apoquel) are irrelevant to this decision.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Cat SCIT for Humans (Curex) | |||||
Cat SLIT Drops for Humans (needle-free) | |||||
Antihistamines + Nasal Steroids |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex delivers cat SCIT as an at-home allergy shot kit at $129/month all-inclusive — the same FDA-standardized Fel d 1 immunotherapy, given as one weekly self-administered shot that removes roughly 39 Year-1 in-clinic visits required for conventional cat SCIT under the Cox 2011 Practice Parameter. The serum is sterile-compounded to USP <797>, a board-certified allergist oversees the plan and supervises your first dose and every dose change live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand.
See if at-home shots are right for youSide effects — what to watch for
Human cat SCIT has the same safety profile as all SCIT. Local injection-site reactions are common; systemic reactions are rare but require the mandatory 30-minute at-home observation period.
Insurance coverage — what to expect
Human cat SCIT is covered by all major US commercial insurers and Medicare Part B when standard medical necessity criteria are met. For full insurer details, see /allergy-shots/cost/does-insurance-cover-allergy-shots.
Skip the insurance hassle — Curex is $129/mo flat, no insurance needed.
Start free assessmentFrequently asked questions
Is the cat allergy shot safe for humans?
Yes. Human cat SCIT with FDA-standardized Fel d 1 extract has one of the best safety profiles of any immunotherapy treatment. Systemic reactions occur in approximately 0.1–0.2% of injection visits (Epstein TG et al., Ann Allergy Asthma Immunol 2014). Fatal anaphylaxis occurs at approximately 1 per 23.3M injection visits. The mandatory 30-minute post-injection observation period at an equipped clinic captures approximately 85% of systemic reactions. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness after an injection, call 911 immediately and use an epinephrine auto-injector if available.
Are Cytopoint and Apoquel cat allergy shots for humans?
No. Cytopoint (Zoetis lokivetmab) is a caninized anti-IL-31 monoclonal antibody injected into dogs every 4–8 weeks for canine atopic dermatitis — the dog's own skin allergy. Apoquel (Zoetis oclacitinib) is an oral JAK inhibitor given to dogs ≥12 months. Both are dog veterinary products. They are not human drugs, do not treat human cat allergy, and are not relevant to any human allergy treatment decision. They appear in consumer search results for 'cat allergy shots for humans' because of overlapping keyword space and because pet-allergy queries often surface veterinary product pages.
What makes FDA-standardized cat extract special?
FDA standardization of cat-hair and cat-pelt extracts (both at 10,000 BAU/mL under Greer license #308, FDA CBER) means the allergen potency — defined by Fel d 1 content per BAU — is consistent across production lots and manufacturers. The therapeutic maintenance target of 1,000–4,000 BAU per injection (approximately 11–17 µg Fel d 1 per Cox 2011 PP3) can be reliably achieved and sustained. This consistency is the structural reason cat SCIT has better RCT evidence than dog SCIT — you cannot run a clean dose-response trial when the dose itself is variable. No other mammalian allergen extract in the US has this standardization.
Can I tell from my allergy test if the cat shot will work?
Component-resolved IgE testing provides the most useful predictive information. High specific IgE to Fel d 1 (the cat-specific secretoglobin) indicates a strong candidate for cat SCIT with good expected outcomes. High Fel d 4 IgE (a lipocalin) with low Fel d 1 IgE suggests cross-reactive sensitization from horse (Equ c 1, 67% identity) or dog (Can f 6, 67% identity) — in which case cat SCIT is less likely to be effective. A board-certified allergist interprets component results alongside your clinical history (which exposures correlate with symptoms, what avoidance measures have been tried) to determine candidacy for cat immunotherapy.
How often do humans need cat allergy shots?
The standard SCIT regimen per the AAAAI/ACAAI Practice Parameter Third Update (Cox 2011) is: approximately 26 weekly injections during the build-up phase (~6 months), then every 2–4 weeks during the maintenance phase for 3–5 years. Year 1 totals approximately 39 in-clinic visits (combining build-up and early maintenance). Years 2–5 require approximately 14–20 visits/year. A 30-minute post-injection observation period is required at every visit. Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957–965; n=103,207) found that 23.9% of patients never returned after the first injection, highlighting the practical challenge of this commitment.
Does removing the cat fix the allergy without shots?
Cat removal significantly reduces new Fel d 1 deposition but does not quickly resolve exposure. Wood RA et al. (JACI 1989) found 7 of 15 homes still had elevated Fel d 1 levels beyond 20 weeks after cat removal. NHANES 2005–2006 (Salo PM et al., JACI 2014;134:350–359) detected Fel d 1 in 99.9% of US homes — including cat-free homes — at approximately 1.0 µg/g geometric mean, largely because Fel d 1 on small airborne particles is transported via clothing, workplaces, and public spaces. For patients with mild sensitization and complete avoidance, removal may be clinically adequate. For patients with ongoing exposure or significant IgE sensitization, immunotherapy is the disease-modifying option.
Related Articles
Allergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreAllergy Desensitization Therapy: Program Guide | Curex
Allergy desensitization therapy is a 3-5 year SCIT program: 24-28 weekly build-up visits, then monthly maintenance. Durham 1999 NEJM: durable remission after course ends.
Read moreAllergy Shots for Pet Dander | Curex Species Guide
Allergy shots for pet dander treat HUMANS sensitized to cat, dog, horse, or small-mammal allergens. Cat has FDA-standardized extract; dog evidence is 'poor and conflicting.'
Read moreTypes of Allergy Injections: Full Guide | Curex
Types of allergy injections include SCIT (immunotherapy), biologics like Xolair and Dupixent, depot steroids, and epinephrine. Only SCIT modifies the underlying disease.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots for humans traditionally mean ~95–119 clinic visits over 3–5 years (23.9% quit, Tkacz 2021). Curex delivers that SCIT at home, $129/mo.
Read moreAllergy Shots for Dog Allergies | Curex Human SCIT Guide
Allergy shots for dog allergies treat HUMANS — not dogs. Dog SCIT evidence is 'poor and conflicting' (Smith 2016). 16.5% of dog-sensitized adults can skip shots entirely.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.